Aclaris Therapeutics, Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Aclaris is a clinical-stage biopharmaceutical company developing therapies for immuno-inflammatory diseases and pursuing strategic partnerships to develop or commercialize its drug candidates. The filing covers the three and nine months ended September 30, 2023, compared with the same periods in 2022.
Key programs include zunsemetinib for rheumatoid arthritis and psoriatic arthritis, ATI-1777 for atopic dermatitis, ATI-2138 for T-cell-mediated autoimmune diseases, and ATI-2231 for oncology and other potential indications. The company discontinued development of zunsemetinib for hidradenitis suppurativa after the Phase 2a study failed to meet its efficacy endpoints.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $9.3 million | $19.0 million | $13.7 million | $22.0 million |
| Operating loss | $(31.6) million | $(20.9) million | $(93.3) million | $(60.8) million |
| Net loss | $(29.3) million | $(20.0) million | $(87.0) million | $(59.3) million |
| Net loss per share | $(0.41) | $(0.30) | $(1.25) | $(0.92) |
| Operating margin | (340.2%) | (109.8%) | (682.2%) | (276.3%) |
| Net margin | (315.2%) | (104.9%) | (635.9%) | (269.4%) |
Revenue consisted primarily of licensing and contract research. Q3 licensing revenue was $8.6 million, including $8.3 million from the Lilly agreement; contract research revenue was $0.7 million. The company does not present gross profit because it does not consider that measure meaningful given its revenue mix.
- Research and development expense was $23.9 million in Q3 and $71.7 million for the first nine months, compared with $23.7 million and $56.7 million, respectively, in the prior-year periods.
- General and administrative expense was $7.1 million in Q3 and $24.2 million for the first nine months, up from $5.8 million and $18.0 million, respectively.
- Stock-based compensation expense was $5.9 million in Q3 and $19.3 million for the first nine months, versus $4.2 million and $10.2 million in the comparable periods.
- Other income increased to $2.3 million in Q3 and $6.3 million for the first nine months, primarily because of higher interest income.
Cash flow, liquidity, debt and capital structure
- Cash, cash equivalents and marketable securities totaled $187.0 million at September 30, 2023, consisting of $39.0 million of cash and cash equivalents and $148.0 million of marketable securities.
- Total liquidity declined from $229.8 million at December 31, 2022, primarily because of operating cash use.
- Net cash used in operating activities was $71.6 million for the first nine months of 2023, compared with $48.5 million in the prior-year period.
- Investing activities provided $38.7 million, principally from net sales and maturities of marketable securities.
- Financing activities provided $26.7 million, including $26.7 million of net proceeds from the April 2023 at-the-market equity offering.
- The company had no ongoing material financing commitments such as a line of credit or guarantees. The filing does not identify material conventional debt; liabilities included $32.5 million of contingent consideration, $2.1 million of operating lease liabilities and $2.2 million related to discontinued operations.
- Accumulated deficit was $769.3 million at September 30, 2023. Management stated that existing cash, cash equivalents and marketable securities should fund operating and capital requirements for more than 12 months from issuance of the financial statements, although additional capital will be required for continued development.
Material changes versus the prior comparable periods
- Q3 revenue decreased $9.7 million, or approximately 51%, and nine-month revenue decreased $8.3 million, or approximately 38%. The primary driver was the absence of the $17.6 million Lilly upfront payment and regulatory milestones recognized in 2022.
- Q3 net loss increased $9.3 million, and the nine-month net loss increased $27.7 million. The deterioration reflected lower revenue and higher research and development and general and administrative spending.
- Nine-month research and development expense increased $15.0 million, driven largely by higher ATI-2138 activity, personnel and stock-based compensation, discovery investment, and zunsemetinib manufacturing and rheumatoid arthritis trial costs.
- The company raised $27.5 million of gross proceeds through the sale of 3.4 million shares under its at-the-market facility in April 2023, compared with $75.0 million of gross proceeds from 4.8 million shares in April 2022.
- EPI Health filed for Chapter 11 bankruptcy in July 2023. The purchaser of the RHOFADE assets did not assume Aclaris’s asset purchase agreement, eliminating expected future royalties and milestones from that arrangement. Aclaris recorded bad debt expense of $0.3 million in Q3 and $1.3 million for the first nine months.
- The contingent consideration liability decreased from $33.1 million at year-end 2022 to $32.5 million at September 30, 2023. The decrease reflected removal of estimated hidradenitis suppurativa sales and higher discount rates, partly offset by a higher probability of success for ATI-2138 and the passage of time.
Guidance, outlook, risks and unusual items
- Management expects continued net losses and negative operating cash flow while advancing clinical, preclinical and discovery programs.
- Expected milestones include topline rheumatoid arthritis data for zunsemetinib in November 2023, ATI-1777 atopic dermatitis data around year-end 2023, psoriatic arthritis data in the first half of 2024, and initiation of an ATI-2138 ulcerative colitis Phase 2a study in early 2024.
- ATI-2138’s Phase 1 study enrolled 60 healthy subjects; preliminary results indicated general tolerability, dose-proportional pharmacokinetics and no serious adverse events.
- Additional capital or partnering transactions will be needed to complete development programs and support discovery activities. Potential financing could dilute existing stockholders or include terms unfavorable to common stockholders.
- Major risks include clinical-trial failure or delay, regulatory nonapproval, inability to secure partners or financing, dependence on third-party manufacturers, intellectual-property challenges, macroeconomic conditions and interest-rate effects on investments.
- The company holds substantial cash and investments at three financial institutions, with most balances exceeding or not subject to federal insurance limits.
- The company reported no material pending legal proceedings and stated that its risk factors had not materially changed from the 2022 Form 10-K.
Most important facts for investors to verify
- Whether the expected zunsemetinib and ATI-1777 clinical readouts occur on schedule and support further development.
- The pace of operating cash burn and whether liquidity remains sufficient for more than 12 months under updated spending assumptions.
- Progress toward the ATI-2138 Phase 2a trial and development plans for ATI-2231.
- The impact of losing future RHOFADE royalties and milestones after the EPI Health bankruptcy.
- Future equity issuance, dilution risk and the availability of additional partnership or financing proceeds.
- The valuation and potential cash impact of the $32.5 million contingent consideration liability and related milestone and royalty obligations.